 |
Pfizer agrees $14bn deal for cancer drug firmPfizer, beating out numerous other bidders, said it agreed to buy US cancer drug company Medivation for $14 billion in cash, adding its blockbuster prostate cancer drug Xtandi to the company's growing oncology roster. Medivati More… |
Tuesday 5 November 2024
